Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

KADIAN

MORPHINE SULFATE

Standard Dose
200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KADIAN is listed in Drugs@FDA under application 020616 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient MORPHINE SULFATE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 200MG Sponsor ALLERGAN Submission history Latest submission status date: 2021-03-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview KADIAN is listed in Drugs@FDA under application 020616 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MORPHINE SULFATE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 200MG Sponsor ALLERGAN Submission history Latest submission status date: 2021-03-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.